Skip Navigation

European Heart Journal 2002 23(20):1557-1559; doi:10.1053/euhj.2002.3290
Copyright © 2002 by the European Society of Cardiology.
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Delahaye, F.
Right arrow Articles by de Gevigney, G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Delahaye, F.
Right arrow Articles by de Gevigney, G.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Editorials

The scourge of coronary disease in diabetic patients: will antibiotics sweeten the pill?

F. Delahaye, E. P. McFadden and G. de Gevigney

Hopital Cardiovasculaire et pneumologique, BP Lyon Montchat, Lyon Cedex. 3, France

References

  1. Erkens JA, Klungel OH, Herings. Use of fluorquinolones is associated with a reduced risk of coronary heart disease in diabetes mellitus type 2 patients. Eur Heart J. 2002;23:1575–1579[Abstract/Free Full Text]
  2. Danesh J, Collins R, Peto R. Chronic infections and coronary heart disease: is there a link? Lancet. 1997;350:430–436[CrossRef][ISI][Medline]
  3. Libby P, Egan D, Skarlatos S. Role of infectious agents in atherosclerosis and restenosis. An assessment of the evidence and need for further research. Circulation. 1997;96:4095–4103[Free Full Text]
  4. Gurfinkel EP, Scirica B. Antibiotic therapy to stabilize vulnerable plaque. Brown DL. Cardiovascular plaque rupture. New York: Marcel Dekker, Inc.; 2002. p. 399–427
  5. Ngeh J, Gupta S. Inflammation and infection in coronary artery disease. Jackson G. Cardiology. Current perspectives. London: Martin Dunitz Ltd; 2002. p. 125–144
  6. Danesh J, Whincup P, Walker M. Chlamydia pneumoniae IgG titres and coronary heart disease: prospective study and meta-analysis. Br Med J. 2000;321:208–213[Abstract/Free Full Text]
  7. Campbell LA, Rosenfeld M, Kuo CC. The role of Chlamydia pneumoniae in athersclerosis. Recent evidence from animal models. Trends Microbiol. 2000;8:255–257[CrossRef][ISI][Medline]
  8. Jackson LA, Campbell LA, Schmidt RA. Specificity of detection of Chlamydia pneumoniae in cardiovascular atheroma: evaluation of the innocent bystander hypothesis. Am J Pathol. 1997;150:1785–1790[Abstract]
  9. Gupta S, Leatham EW, Carrington D, Mendall MA, Kaski JC, Camm AJ. Elevated Chlamydia pneumoniae antibodies, cardiovascular events, and azithromycin in male survivors of myocardial infarction. Circulation. 1997;96:404–407[Abstract/Free Full Text]
  10. Gurfinkel EP, Bozovich G, Daroca A, Beck E, Mautner B. Randomised trial of roxithromycin in non-Q-wave coronary syndromes: ROXIS pilot study. Lancet. 1997;350:404–407[CrossRef][ISI][Medline]
  11. Gurfinkel EP, Bozovich G, Beck E, Testa E, Livellara B, Mautner B. Treatment with the antibiotic roxithromycin in patients with non-Q-wave coronary syndromes. The final report of the ROXIS study. Eur Heart J. 1999;20:121–127[Abstract/Free Full Text]
  12. Anderson JL, Muhlestein JB, Carlquist J. Randomized secondary prevention trial of azithromycin in patients with coronary artery disease and serological evidence for Chlamydia penumoniae infection. The azithromycin in coronary artery disease: elimination of myocardial infection with Chlamydia (ACADEMIC) study. Circulation. 1999;99:1540–1547[Abstract/Free Full Text]
  13. Muhlestein JB, Anderson JL, Carlquist JF. Randomized secondary prevention trial of azithromycin in patients with coronary artery disease: primary clinical results of the ACADEMIC study. Circulation. 2000;102:1755–1760[Abstract/Free Full Text]
  14. Black PN. Anti-inflammatory effects of macrolide antibiotics. Eur Respir J. 1997;10:971–972[CrossRef][ISI][Medline]
  15. Martin D, Bursill J, Qui MR, Breit SN, Campbell T. Alternative hypothesis for efficacy of macrolides in acute coronary syndromes. Lancet. 1998;351:1858–1859[CrossRef][ISI][Medline]

Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?



This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Delahaye, F.
Right arrow Articles by de Gevigney, G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Delahaye, F.
Right arrow Articles by de Gevigney, G.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?